CMS Finalizes Most-Favored-Nation Pricing Model for Medicare Part B Drugs
CMS has finalized a Medicare Part B drug-pricing model built on most-favored-nation benchmarks, a pricing-policy shift with direct implications for manufacturer reimbursement, contract economics and litigation risk.
What the reporting indicates: CMS has finalized the "GLOBE" model, applying most-favored-nation drug-pricing logic to drugs furnished under Medicare Part B, per a Jones Day alert dated 11 October 2026. Only the alert's headline and framing were available in this cluster, so the model's operative mechanics, scope, covered drugs, implementation timetable and any transition provisions should be verified against the final rule text and sub-regulatory guidance before reliance.
Why sophisticated counsel should care. Part B is a large, fast-growing channel for high-cost specialty, oncology and biologic products, and a benchmark-linked pricing construct is not a rebate tweak: it can reach list prices, price-reporting obligations, and the economics of distribution agreements with buy-and-bill providers, hospitals, distributors and PBMs. For manufacturer, provider and plan-side clients, finalization resets the baseline for pricing negotiations, revenue forecasting, compliance programs and government-pricing exposure.
Practical next steps. Read the final rule against existing contract terms and price-reporting workflows; identify products and channels in scope; calibrate exposure to pricing-model litigation, which has been active in this space. Watch for CMS implementation materials, state and plan reaction, and congressional or judicial developments.